Blueprint medicines did a deal with Hoffman La Roche in 2016 ...their IPO was in 2015 and they were as far as I can see in phase 1 trials but a number of them,working with small molecules.You can read the article especially relating to small molecules and can see we are doing just the same as they are, same goals,same effect,with our PTX 200 and PTX 100. We have a potentially huge MC increase in PTX that is not factored in.
